en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


4/2009
vol. 47
 
Share:
Share:
abstract:
Original paper

Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects

Lidia Rutkowska-Sak
,
Maria Rell-Bakalarska
,
Barbara Lisowska

Reumatologia 2009; 47, 4: 207–211
Online publish date: 2009/10/19
View full text Get citation
 
The aim of our present data was to compare the gastrological side effects of oral versus subcutaneous (SC) administration of methotrexate in patients with long-lasting rheumatoid arthritis (RA). We compared the intensity of gastrological side effects such as nausea, vomiting, loss of appetite, abdominal pain and diarrhea in patients who received methotrexate (MTX) in oral or subcutaneous doses of either 7.5 mg or 15 mg weekly. The survey research was used to evaluate the intensity of the above-mentioned side effects. The questionnaires were completed by a doctor, who conducted a structured interview with patients. Patients receiving oral MTX had more intense gastrological side effects. There was a correlation between dose of oral MTX and intensity of side effects. Patients receiving 15 mg MTX orally had significant severe vomiting and loss of appetite (p < 0.05). Nausea and loss of appetite turned out to be the most frequent side effects in patients receiving SC MTX 15 mg/weekly. In contrast to patients from the oral MTX groups none from the SC MTX groups exhibited vomiting or diarrhea. We found that SC MTX administration demonstrated a significant reduction of gastrological side effects’ intensity compared with oral administration of the same MTX dosage among patients with long-lasting RA. We also observed the possibility of dosage reduction of other DMARDs. Using SC MTX therapy allowed 50% oral dosage reduction in 14.6% of patients among patients who received them.
keywords:

oral, subcutaneous methotrexate, intensity of gastrointestinal side effects




Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.